Manage Emotions to Reduce Aggression (MERA)
Launched by VA OFFICE OF RESEARCH AND DEVELOPMENT · Mar 8, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Manage Emotions to Reduce Aggression (MERA) trial is studying how a short treatment program can help Veterans who struggle with controlling their aggressive feelings, especially those with post-traumatic stress disorder (PTSD) after serving in combat since 9/11. The program includes three sessions focused on improving how Veterans manage their emotions, which can lead to a decrease in impulsive aggressive behavior. This research aims to make it easier for Veterans to start effective PTSD treatments by helping them feel more in control of their emotions.
To participate in this study, Veterans must have served in combat zones since 9/11, be experiencing symptoms of PTSD, and have engaged in aggressive acts like yelling or throwing things recently. It's important that they can have someone close to them verify these behaviors. Participants should be willing to keep their current mental health medications unchanged during the study. It's also crucial that they are not currently feeling suicidal or having thoughts of harming others. If eligible, participants can expect to attend three sessions that focus on managing emotions and reducing aggression, which could help them on their journey to recovery from PTSD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and female Veterans who deployed to combat zones since 9/11.
- • 2. Currently meets criteria for full or subthreshold PTSD, determined by the Clinician-Administered PTSD Scale for DSM-5
- • 3. Engaged in at least 3 self-reported aggressive acts (e.g., yelling, throwing objects, hitting objects/people) in the last month, measured by the Overt Aggression Scale
- • 4. Impulsive aggression is his/her primary form of aggression, determined by the Impulsive Premeditated Aggression Scale
- • 5. Each Veteran must allow an independent aggression rater (live-in partner, family member, or roommate above 18 years of age)\] verify the number of aggressive acts, using the Overt Aggression Scale.
- • 6. Agreement not to change psychotropic medications through the duration of the study.
- Exclusion Criteria:
- • 1. Currently suicidal with intent of self-harm in the last week.
- • 2. Currently homicidal with plans to hurt a specific person.
- • 3. Unable to complete self-report measures.
- • 4. Meets diagnostic criteria for bipolar disorder or psychotic disorder.
- • 5. Had a psychotropic medication change within 4 weeks prior to the baseline assessment. Veterans receiving general mental health services or engaging in usual care will be allowed to participate.
About Va Office Of Research And Development
The VA Office of Research and Development (ORD) is dedicated to advancing the health and well-being of veterans through innovative research initiatives. As a pivotal sponsor of clinical trials, ORD focuses on a broad spectrum of health-related topics, including mental health, rehabilitation, and chronic disease management, ensuring that findings are directly applicable to the unique needs of the veteran population. With a commitment to scientific excellence and collaboration, ORD promotes rigorous study designs and ethical standards, facilitating the translation of research discoveries into improved clinical practices and policies that enhance veteran care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Houston, Texas, United States
Patients applied
Trial Officials
Shannon R. Miles, PhD
Principal Investigator
James A. Haley Veterans' Hospital, Tampa, FL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials